AstraZeneca is the first pharmaceutical company to use IntraLinks’ services to speed and protect the intense information and document exchange activities required to conduct global clinical drug trials.
These trials take years, and every day we save can result in therapeutic alternatives for patients. By incorporating IntraLinks’ proven, secure services into our clinical trials processes, we have the potential to accelerate drug development, said Dr Ron Krall, senior vice president, Clinical Development and Medical Affairs for AstraZeneca.
AstraZeneca now uses IntraLinks to exchange information, including documents and data, among scientists and physicians involved in clinical trials. IntraLinks digital workspaces enable project managers at AstraZeneca to easily control and monitor who accesses information and when. In addition, the IntraLinks solution enables compliance with regulatory requirements such as document maintenance and auditability. IntraLinks services, which include security-rich, Internet-based software and twenty four seven service and support, were designed to comply with FDA and ICH system validation requirements.
AstraZeneca is exhibiting real leadership in adopting e-Business strategies to drive efficiency in clinical drug trials, said James P. Dougherty, president and CEO of IntraLinks in a press announcement. We are especially pleased to see adoption of IntraLinks’ services by the pharmaceutical industry, a market that needs to exchange large volumes of information among multiple parties and comply with extensive regulations. We are confident of our success in this sector because IntraLinks is the industry standard for online collaboration in markets with similar characteristics, including financial and legal services.
